Press release
United States Blood Cancer Drugs Market 2025 | Growth Drivers, Key Players & Investment Opportunities
Blood Cancer Drugs Market
The Global Blood Cancer Drugs Market size reached USD 63 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 113.5 billion by 2031. The global blood cancer drugs market is expected to exhibit a CAGR of 7.8% during the forecast period 2024-2031.
Recent Mergers and Acquisitions;
United States:
✅ In August 2025, Citius Pharmaceuticals received FDA approval for its blood cancer therapy, Lymphir, targeting relapsed cutaneous T-cell lymphoma. The treatment showed a 36.2% response rate in clinical trials, though it carries a boxed warning for capillary leak syndrome.
✅ In May 2025, Helix BioPharma acquired oncology assets from Laevoroc Immunology AG for CHF 5.3 million. This acquisition enhances Helix's pipeline in blood cancer therapies, focusing on novel treatments for hematologic malignancies.
✅ In March 2024, BeiGene's Brukinsa, in combination with Roche's Gazyva, gained FDA accelerated approval for treating relapsed or refractory follicular lymphoma after at least two prior therapies. This combination demonstrated significant efficacy in mid-stage studies.
✅ In November 2024, Syndax Pharmaceuticals' Revuforj (revumenib) was approved by the FDA for treating acute leukemia with KMT2A translocation in both adults and children. The menin inhibitor achieved a 21% complete remission rate in clinical trials.
Japan:
✅ In July 2025, Asahi Kasei Life Science announced plans to construct a new spinning plant in Nobeoka City, Miyazaki, Japan, to expand production for its Planova line of virus removal filters. The facility is expected to start operations in January 2030.
✅ In May 2025, Servier announced the acquisition of BioNova's acute leukemia asset. This strategic move bolsters Servier's leadership in blood cancers, adding a targeted therapy to its hematology pipeline.
✅ In August 2024, Sanofi's Sarclisa (isatuximab) gained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for use in conjunction with VRd to treat newly diagnosed multiple myeloma. This combination therapy aims to improve patient outcomes in early-stage multiple myeloma.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/blood-cancer-drugs-market?sb
Blood Cancer Drugs are therapeutic medications used to treat hematologic malignancies such as leukemia, lymphoma, and multiple myeloma. They include chemotherapy, targeted therapies, immunotherapies, and supportive treatments designed to kill cancer cells, inhibit their growth, and improve patient survival and quality of life.
Key Players:
-> Amgen Inc., AstraZeneca Plc, Takeda Pharmaceutical Company Ltd, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead Sciences Inc., Daiichi Sankyo Company Ltd, and UCB SA.
Growth Forecast Projected:
The Global Blood Cancer Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Research Process:
Both primary and secondary data sources have been used in the global Blood Cancer Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=blood-cancer-drugs-market
Key Segments:
➥ By Type: Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma
➥ By Drugs Type: Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others
➥ By Route of Administration: Oral, Parenteral, Others
➥ By End User: Hospitals, Clinics, Ambulatory Surgical Centers
Regional Analysis for Blood Cancer Drugs Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.
Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.
Chapter 3: Offers an in-depth look at the competitive landscape among Blood Cancer Drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.
Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.
Chapters 5 & 6: Analyze Blood Cancer Drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.
Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.
Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.
Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.
Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/blood-cancer-drugs-market?sb
FAQ
What is the current size of the Blood Cancer Drugs Market?
A: In 2022, the Blood Cancer Drugs Market was valued at USD 63 billion, reflecting its strong industry presence.
Q2: How large is the Blood Cancer Drugs Market expected to be by 2031?
A: By 2031, industry forecasts suggest the Blood Cancer Drugs Market will grow to around USD 113.5 billion, demonstrating significant expansion.
Q3: What is the growth rate of the Blood Cancer Drugs Market?
A: The market is projected to expand at a compound annual growth rate (CAGR) of 7.8% during the forecast period from 2024 to 2031.
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Blood Cancer Drugs Market 2025 | Growth Drivers, Key Players & Investment Opportunities here
News-ID: 4192282 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
United States Virtual Clinical Trials Market 2025 | Growth Drivers, Key Players …
Market Size and Growth
The Global Virtual Clinical Trials Market reached US$ 8.95 billion in 2024 and is expected to reach US$ 14.42 billion by 2033, growing at a CAGR of 5.5% during the forecast period 2025-2033.
Key Development:
United States: Recent Industry Developments
✅ In September 2025, IQVIA launched its Clinical Trial Financial Suite, an AI-enabled platform designed to streamline financial management across clinical trials. This initiative aims to eliminate inefficiencies caused by…
United States Biodegradable Algae Water Bottles Market 2025 | Growth Drivers, In …
Market Size and Growth
Biodegradable Algae Water Bottles Market growing at a High CAGR between the forecast period (2024-2031).
Recent Mergers and Acquisitions
United States:
✅ In September 2025, the biodegradable algae water bottle market in the U.S. was valued at approximately $500 million. This reflects a growing consumer preference for sustainable packaging solutions.
✅ In July 2025, leading companies like Paper Water Bottle and Choose Water are at the forefront of this innovation,…
United States Cosmetic Tubes Market 2025 | Trends, Forecast & Competitive Insigh …
Market Size and Growth
The cosmetic tubes market is estimated to reach at high CAGR during the forecast period (2024-2031).
Recent Mergers and Acquisitions:
Cosmetic Tubes Industry: Recent M&A Developments
United States
✅ In January 2025, International Paper acquired DS Smith, a UK-based packaging company, in a deal valued at $9.9 billion. This strategic move aims to expand International Paper's footprint in the European market and strengthen its position in the packaging industry.
✅ In…
United States DNA/RNA Extraction Kit Market 2025 | Growth Drivers, Key Players & …
Market Size and Growth
The Global "DNA/RNA Extraction Kit Market" is expected to reach at a high CAGR during the forecast period (2024-2031).
Recent Mergers and Acquisitions
✅ In 2025, Takara Bio expanded investments in RNA extraction automation for precision medicine, reflecting a focus on enhancing throughput and consistency in nucleic acid workflows in Japan
✅ In the past 9 months (2024-2025), Thermo Fisher Scientific introduced the Applied Biosystems MagMAX Sequential DNA/RNA Kit,…
More Releases for Drugs
Generic Drugs Market Application Anti-Infective Drugs, Anti-Arthritis Drugs, Ant …
Generic drugs are the medications that are developed to be similar to a medicine that is already commercially available in the market with a brand name. The generic drug is similar to the medicine available in terms of dosage, safety and strength, mode of administration, quality and intended use. Due to the similarities, generic drugs are capable of treating various diseases. Generic drugs are most cost effective than the branded…
Cytotoxic Drugs Market Growing Demand for Antimetabolite Drugs
According to Precision Business Insights (PBI), the latest report, the cytotoxic drugs market is expected to be valued at USD 15,927.2 million in 2022 and is poised to grow at a significant CAGR of 2.2% over 2022-2028. The primary drivers of the expansion of the global cytotoxic drugs market include the increasing prevalence of cancer diseases, the increasing use and approval of cytotoxic drugs, and the increasing consumption of alcohol…
Global Antithrombotic Drugs Market | Global Antithrombotic Drugs Industry | Glob …
Antithrombotic drugs are special drugs that help to prevent the formation of thrombus or clot. These drugs are used to reduce the formation of blood clots by reducing the capability of body to form a blood clot. Antithrombotic drugs act by preventing the production of vitamin K in the liver. Anticoagulant, antiplatelet, and thrombolytic agents are different types of antithrombotic agents that act by different clotting processes. Arterial & venous…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
Hepatitis Drugs Market by Therapeutics, Diagnostics, Patient, Drugs Policy
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market.
Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market
Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest…
Epilepsy Drugs Market by Country, Drugs, Company & Forecast
For More Information:
https://renub-research.blogspot.com/2019/04/the-factors-that-are-driving-global.html
Epilepsy is a chronic disease in which patient’s brain activities become abnormal due to seizures. Seizure is an unexpected rush of electrical activity in the brain. Seizure is categorized by two types - generalized seizures and focal or partial seizures. Generalized seizures affect the whole brain whereas focal or partial seizures affect just one part of the brain. Global epilepsy drugs market is expected to cross US$…
